NO962188L - Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav - Google Patents

Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav

Info

Publication number
NO962188L
NO962188L NO962188A NO962188A NO962188L NO 962188 L NO962188 L NO 962188L NO 962188 A NO962188 A NO 962188A NO 962188 A NO962188 A NO 962188A NO 962188 L NO962188 L NO 962188L
Authority
NO
Norway
Prior art keywords
proteins
methods
dna encoding
apoptosis modulating
novel apoptosis
Prior art date
Application number
NO962188A
Other languages
English (en)
Norwegian (no)
Other versions
NO962188D0 (no
Inventor
Michael C Kiefer
Philip J Barr
Original Assignee
Lxr Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lxr Biotechnology Inc filed Critical Lxr Biotechnology Inc
Publication of NO962188D0 publication Critical patent/NO962188D0/no
Publication of NO962188L publication Critical patent/NO962188L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
NO962188A 1993-11-30 1996-05-29 Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav NO962188L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16006793A 1993-11-30 1993-11-30
US32015794A 1994-10-07 1994-10-07
PCT/US1994/013930 WO1995015084A1 (en) 1993-11-30 1994-11-30 Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
NO962188D0 NO962188D0 (no) 1996-05-29
NO962188L true NO962188L (no) 1996-07-23

Family

ID=26856568

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962188A NO962188L (no) 1993-11-30 1996-05-29 Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav

Country Status (14)

Country Link
US (7) US6586395B1 (de)
EP (1) EP0731636B1 (de)
JP (4) JP4129055B2 (de)
CN (1) CN1139871A (de)
AT (1) ATE315643T1 (de)
AU (1) AU688839B2 (de)
CA (1) CA2177827C (de)
DE (1) DE69434614T2 (de)
ES (1) ES2256843T3 (de)
FI (1) FI962247L (de)
HU (1) HUT74276A (de)
NO (1) NO962188L (de)
NZ (1) NZ277946A (de)
WO (1) WO1995015084A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ277946A (en) 1993-11-30 1998-03-25 Lxr Biotechnology Inc Apoptosis modulating protein and nucleotide sequence compositions using bcl-2 homologs termed cdn-1, cdn-2 and cdn3
US5998131A (en) * 1994-10-07 1999-12-07 Lxr Biotechnology, Inc. Screening methods for the identification of compounds capable of abrogating BaK-BHRF-1 protein interactions
JPH1189573A (ja) * 1994-10-14 1999-04-06 Yutaka Shindo アポトーシス関与遺伝子
AU5568396A (en) * 1995-04-20 1996-11-07 Lxr Biotechnology Inc. Methods of screening for therapeutic agents using novel apop tosis-modulating proteins
WO1998035659A1 (en) * 1997-02-18 1998-08-20 Lxr Biotechnology Inc. Bak promotor expression system
AU6679498A (en) * 1997-03-20 1998-10-12 Lxr Biotechnology Inc. A novel bak binding protein, dna encoding the protein, and methods of use thereof
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US6218144B1 (en) * 1997-06-30 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Costal2 genes and their uses
US6641998B2 (en) * 1997-10-10 2003-11-04 Stratagene Methods and kits to enrich for desired nucleic acid sequences
WO2000017648A1 (en) * 1998-09-24 2000-03-30 Promega Corporation Apoptosis marker antibodies and methods of use
MXPA01008626A (es) 1999-02-26 2002-04-24 Univ Johns Hopkins Inhibidor novedoso de muerte programada de celula.
US6737511B1 (en) * 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
AU2001231009A1 (en) 2000-01-21 2001-07-31 Beth Israel Deaconess Medical Center Use of pro-apoptotic factors in treatment of atherosclerosis
EP1349929A2 (de) * 2000-07-14 2003-10-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Apoptose-induzierende dna-sequenzen
US20030170722A1 (en) * 2001-03-02 2003-09-11 Mcfadden Grant Methods and reagents for regulating apoptosis
EP1253200A1 (de) * 2001-04-25 2002-10-30 Société des Produits Nestlé S.A. Kakao-Polypeptide und ihre Anwendung zur Herstellung von Kakao- und Schokoladenaroma
CN100352510C (zh) * 2001-10-03 2007-12-05 拜奥尼茨生命科学公司 可用于治疗的三甘醇胆甾烯基寡核苷酸
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
WO2004050858A2 (en) * 2002-12-04 2004-06-17 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004072225A2 (en) * 2003-02-12 2004-08-26 Ramot At Tel Aviv University Ltd. Transgenic fungi expressing bcl-2 and methods of using bcl-2 or portions thereof for improving biomass production, survival, longevity, stress resistance and pathogenicity of fungi
CA2530582C (en) * 2003-06-23 2014-09-09 A&G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
EP1660010B1 (de) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Zusammensetzungen und verfahren zur wiederherstellung der empfänglichkeit für eine behandlung mit her2-antagonisten
EP2511298B1 (de) * 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Behandlung von Krebs unter Verwendung von menschlichen FZD Rezeptoren
WO2011056886A2 (en) * 2009-11-03 2011-05-12 The Johns Hopkins University Method and composition for generating programmed cell death resistant algal cells
EP2418286A1 (de) * 2010-08-10 2012-02-15 QIAGEN GmbH Verbessertes Verfahren zur isothermalen Amplifikation von Nukleinsäuren
US20130166458A1 (en) * 2011-12-22 2013-06-27 Embraer S.A. System and method for remote and automatic assessment of structural damage and repair
WO2022087238A1 (en) * 2020-10-21 2022-04-28 Wisconsin Alumni Research Foundation Anti-apoptotic vector and method of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5395767A (en) 1992-06-22 1995-03-07 Regents Of The University Of California Gene for ataxia-telangiectasia complementation group D (ATDC)
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
EP0711174A4 (de) 1993-06-24 1997-11-12 Gen Hospital Corp Gene für den programmierten zelltod und proteine
WO1995005738A1 (en) 1993-08-20 1995-03-02 Massachusetts Institute Of Technology Anticancer agents and apoptosis
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
NZ277946A (en) * 1993-11-30 1998-03-25 Lxr Biotechnology Inc Apoptosis modulating protein and nucleotide sequence compositions using bcl-2 homologs termed cdn-1, cdn-2 and cdn3
US5672686A (en) * 1994-08-09 1997-09-30 Immunogen, Inc. Bcl-Y - specific antibodies
AU5568396A (en) * 1995-04-20 1996-11-07 Lxr Biotechnology Inc. Methods of screening for therapeutic agents using novel apop tosis-modulating proteins
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7

Also Published As

Publication number Publication date
JPH09509567A (ja) 1997-09-30
AU688839B2 (en) 1998-03-19
NO962188D0 (no) 1996-05-29
CA2177827C (en) 2007-08-28
US7108989B2 (en) 2006-09-19
US5770443A (en) 1998-06-23
JP2006061159A (ja) 2006-03-09
NZ277946A (en) 1998-03-25
DE69434614T2 (de) 2006-10-05
CA2177827A1 (en) 1995-06-08
ES2256843T3 (es) 2006-07-16
HUT74276A (en) 1996-11-28
EP0731636A1 (de) 1996-09-18
US20050164284A1 (en) 2005-07-28
US20070117748A1 (en) 2007-05-24
US20030008837A1 (en) 2003-01-09
WO1995015084A1 (en) 1995-06-08
EP0731636B1 (de) 2006-01-11
FI962247A7 (fi) 1996-07-22
HU9601448D0 (en) 1996-07-29
US6015687A (en) 2000-01-18
FI962247L (fi) 1996-07-22
US6903195B1 (en) 2005-06-07
JP2007252391A (ja) 2007-10-04
JP4129055B2 (ja) 2008-07-30
FI962247A0 (fi) 1996-05-29
AU1335195A (en) 1995-06-19
CN1139871A (zh) 1997-01-08
US7754418B2 (en) 2010-07-13
JP2009189377A (ja) 2009-08-27
ATE315643T1 (de) 2006-02-15
EP0731636A4 (de) 1998-04-15
DE69434614D1 (de) 2006-04-06
US6586395B1 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
NO962188D0 (no) Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav
NO961812L (no) Humanproteaseinhibitorer av Kunitz-type
DE68929387D1 (de) Interleukin-1-Inhibitoren
AU7301898A (en) Survivin, a protein that inhibits cellular apoptosis, and its modulation
DK0652960T3 (da) Cyklisk GMP-bindende, cyklisk GMP-specifikke phosphodiesterasematerialer og fremgangsmåder
DK0741694T3 (da) Phenyleddikesyrederivater, fremgangsmåder og mellemprodukter til deres fremstilling og midler indeholdende disse
MY120693A (en) Human bikunin
DK240090A (da) Dna og anvendelse deraf
EA199700186A1 (ru) Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
NO963818L (no) Forhöyet utskillelse av polypeptider
DK306386D0 (da) Fibronectin og polypeptidsekvenser omfattende de collagenbindende og/eller fibrinbindende dele deraf, cdna-sekvenser, som koder herfor, vektorer indeholdende cdna-sekvenserne mikroorganismer transformeret dermed og fremgangsmaade til rensning af stoffer
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
DK372086D0 (da) Fremgangsmaade til rekombinant-dna-syntese af en serinproteaseinhibitor og dna-sekvenser, som er nyttige derved
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
ATE178072T1 (de) Neuartige polypeptide und ihre verwendung
DK0433117T3 (da) Nye polypeptider, DNA-sekvenser, som muliggør ekspression deraf, samt fremstilling og anvendelse deraf.
DK0793721T3 (da) Peptider, der er i stand til at binde sig til GAP-proteinets SH3-domæne, nukleotidsekvenser, der koder derfor, fremstilling og anvendelse deraf
DK0403458T3 (da) Hidtil ukendte polypeptider og anvendelse deraf
ES2165358T3 (es) Utilizaciones de la proteinquinasa de neurofilamento/tau pk40.
DK130290A (da) Lymfokiner, dna-sekvenser, som koder for disse lymfokiner og farmaceutiske midler indeholdende disse lymfokiner
NO20000889L (no) Oligonukleotider som muliggjør identifikasjon av amiderte polypeptidhormoner
FR2654430B1 (fr) Nouveaux derives de peptides, utilisables comme inhibiteurs des collagenases bacteriennes.
SE8501412L (sv) Teltenhet
ATE104344T1 (de) Gereinigte ubiquitin-hydrolase, diese kodierende dns-sequenzen und ihre verwendung zur gewinnung von polypeptiden.
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi